15th INTERNATIONAL CONGRESS OF PARKINSON'S

Abstracts
by topic
112
Abstracts by Topic
747 Role of serotoninergic dysfunction in the pathophysiology of
depression in Parkinson’s disease: A PET 18 F-MPPF study
B. Ballanger, H. Klinger, J. Eche, D. Le Bars, E. Broussolle, S. Thobois
(Bron, France)
748 Altered corticoputaminal connectivity in multiple system atrophy
M. Tir, P. Besson, C. Delmaire, J. Salleron, A. Destee, L. Defebvre
(Versailles, France)
749 Higher GABA concentrations in the brainstem in Parkinson’s disease
by 1H MRS at 7T
P.J. Tuite, U.E. Emir, G. Oz (Minneapolis, Minnesota, USA)
750 White matter hyperintensities in multiple system atrophy
M. Umoto, R. Ando, H. Miwa, T. Kondo (Wakayama-City, Japan)
751 Response inhibition in myoclonus dystonia – An fMRI study
S.M.A. van der Salm, J.N. van der Meer, D.L. de Boer, A.J. Nederveen,
D.J. Veltman, A.-F. van Rootselaar, M.A.J. Tijssen (Amsterdam, NH,
Netherlands)
752 Predictive value of ß-CIT scan vs. clinical rating for further
progression of Parkinson’s disease
T. Vogt, K. Kramer, M. Gartenschläger (Mainz, Germany)
753 Clinical and neuroimaging studies in vascular parkinsonism and
vascular dementia
Y.-H. Weng, R.-S. Chen, K.-J. Lin (Taipei, Taiwan)
754 The relationship between disrupted functional connectivity and
structural damage in PSP: A resting state fMRI, DTI, VBM study
J.L. Whitwell, R. Avula, A. Master, P. Vemuri, M.L. Senjem, D.T. Jones,
C.R. Jack, K.A. Josephs (Rochester, Minnesota, USA)
755 Striatal pattern of [18F]FP-CIT binding is similar between pure
akinesia and progressive supranuclear palsy
S. You, J.S. Kim, C.S. Lee (Seoul, Korea)
756 Developing an MRI-based biomarker for early diagnosis of
Parkinson’s disease
Z. Zhang, Y. AI, A. Andersen, R. Grondin, G. Gerhardt (Lexington,
Kentucky, USA)
757 Movement disorders in mevalonic aciduria
J. Zyss, M. Vlaicu, S. Gerber, M. Rodallec, C. Gauthier, M. Zuber
(Paris, France)
Neuropharmacology
758 Memantine for gait disorders, axial rigidity and attention deficit in
Parkinson’s disease? A double blind placebo controlled study
C. Moreau, A. Delval, K. Dujardin, M. Delliaux, V. Tiffreau, A. Kreisler,
C. Simonin, J.-L. Blatt, R. Bordet, A. Destée, L. Defebvre, D. Devos
(Lille, France)
759 The incidence of amantadine induced livedo reticularis in Parkinson’s
disease patients
A. Fattah, A.Q. Rana, I. Siddiqi (Toronto, Canada)
760 Treating idiopathic Parkinson’s disease (IPD) in patients with
schizophrenia
J.H. Friedman (Providence, Rhode Island, USA)
762 NOS inhibitors improve L-DOPA-induced dyskinesias in
experimental models of parkinsonism
J.E. Yuste, M. Bermúdez, F. Ros Bernal, C. Barcia, J. Martin, E. Del Bel,
E. Fernández Villalba, M.-T. Herrero (Murcia, Spain)
763 Neuroprotective role of 17b-estradiol administration on altered age
related neuronal parameters in female rats
P. Kumar, R.K. Kale, N.Z. Baquer (New Delhi, Delhi, India)
764 Safety, tolerability, and preliminary efficacy of NP002 for levodopainduced
dyskinesias (LIDS) in Parkinson’s disease (PD) patients
A. Lieberman, np002 Study Investigators (Phoenix, Arizona, USA)
765 A five year follow up of a family affected by mutation of KNCA1
gene with myokymia and muscle cramps but not ataxia
N. Moghimi, M.L. Rabin, B. Jabbari (New Haven, Connecticut, USA)
766 Duration of L-dopa and dopamine agonist monotherapy in
Parkinson’s disease
T. Nissen, E.J. Newman, K.A. Grosset, M. Daghem, G. Pal, M. Stewart,
P. Odin, G.J. Macphee, D.G. Grosset (Glasgow, United Kingdom)
767 Effect of pramipexole, bromocriptine and imipraime on the
expression of DRD2 and DRD3 in brain tissues using real time PCR
M. Kaneta, N. Tokunaga, M. Nagai, N. Nishikawa, M. Nomoto
(Tohon, Ehime, Japan)
768 Patients’ perspective of tetrabenazine 2 years after FDA approval
A.M. Palao, C.B. Hunter, J.J. Jankovic (Houston, Texas, USA)
769 Importance of parallel history in Parkinson’s disease patients on
dopamine agonists!
A.Q. Rana, A. Fattah, I. Siddiqi (Toronto, Canada)
770 Multiple impulse control disorders and punding with a single
dopamine agonist
A.Q. Rana, A. Fattah, I. Siddiqi (Toronto, Canada)
771 Potential therapeutic application of Mucuna pruriens for Parkinson’s
disease
M. Sakata, H. Nishimori, M. Nomoto, T. Kondo (Wakayama City,
Wakayama Prof, Japan)
772 Dopaminergic challenge-tests in parkinsonian syndromes
S. Seiler, K. Wenzel, P. Schwingenschuh, C.N. Homann, E. Ott (Graz,
Steiermark, Austria)
773 Rotigotine and demented Parkinson’s disease patients: A therapeutic
option
M.H. Strothjohann, G.A. Fuchs (Wolfach, Germany)
Non-motor Aspects of Movement Disorders (not PD):
Dysautonomia
774 A study of autonomic function in Parkinson’s disease using heart rate
variability
S. Chandran, A. Meghana, R. Kisan, T.R. Raju, P.K. Pal,
T.N. Sathyaprabha (Bangalore, Karnataka, India)
775 Effects of high-dose ropinirole on sexual function in Parkinson’s
disease
N. Kovacs, J. Janszky, F. Nagy (Pecs, Hungary)
776 Plasma ghrelin levels are affected in patients with multiple system
atrophy: Evidence of gut-brain axis dysfunction
T. Ozawa, J. Tokunaga, M. Arakawa, R. Takeuchi, O. Onodera,
M. Nishizawa (Niigata, Japan)
777 Alpha-synuclein in colonic submucosa in early untreated Parkinson’s
disease
K.M. Shannon, A. Keshavarzian, E. Mutlu, H.B. Dodiya, D. Daian,
J.A. Jaglin, J.H. Kordower (Chicago, Illinois, USA)